TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Continuous Infusion Piperacillin-tazobactam for the Treatment of Cystic Fibrosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Diagnosis of cystic fibrosis~2. 8 years of age or greater~3. Chronic or intermittent infection with Pseudomonas aeruginosa as defined by the Leeds Criteria~4. Pulmonary exacerbation as defined by Fuchs et al.~Exclusion Criteria:~1. Admission for greater than 48 hours prior to enrollment~2. Isolation of Burkholderia spp. in a respiratory tract culture in the prior 12 months~3. Current treatment for allergic bronchopulmonary aspergillosis~4. Pregnant or breast feeding~5. History of solid organ transplantation~6. Renal impairment at time of randomization (\< 40 mL/min as calculated by the Cockcroft-Gault equation24 ¬for adults or the Schwartz equation45 for those \< 18 years of age) or receipt of hemodialysis~7. Allergy to study medication

- Gender: ALL
- Minimum Age: 8 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intermittent Infusion piperacillin-tazobactam (Type: ACTIVE_COMPARATOR): Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams), divided in four equal doses, administered over 30 minutes, four times a day
- Continuous infusion piperacillin-tazobactam (Type: EXPERIMENTAL): Piperacillin-tazobactam administered at a dose of 400 mg/kg/day (maximum of 16 grams) as a continuous infusion over 24 hours, once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Randomized Study of SYNSORB Pk in Children With E. Coli-Associated Hemolytic Uremic Syndrome

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
PROTOCOL ENTRY CRITERIA:~--Disease Characteristics--~* Clinically diagnosed E. coli-associated diarrhea-associated hemolytic uremic syndrome (HUS)~* Diarrheal prodrome within 7 days before onset of disease~* No HUS associated with the following: Hereditary Post-bone marrow transplantation Streptococcus pneumoniae infection~* No prior catastrophic complications~--Patient Characteristics--~* Hematopoietic: Thrombocytopenia less than 140,000/mm3 Fragmented red blood cells~* Renal: Renal involvement (hematuria, proteinuria, or azotemia) No underlying glomerular disease~* Other: HIV negative No pre-existing structural abnormality or dysmotility syndrome of the gastrointestinal tract No inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis)

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- SYNSORB Pk (Type: EXPERIMENTAL): Oral Shiga toxin-binding agent (500 mg/kg/day)
- Placebo (Type: PLACEBO_COMPARATOR): Cornmeal placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Descartes-11 in Multiple Myeloma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Active multiple myeloma that is refractory after at least 2 prior lines of therapy;~* measurable disease;~* adequate vital organ function; and~* no active infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose-Escalation (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dose Escalation Safety and Pharmacokinetic Study of AVE9633 as Single Agent in Relapsed/Refractory CD33-Positive Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients with CD33-positive acute myeloid leukemia, refractory or relapsed after standard treatment with no curative option available~* ECOG performance status 0 to 2~Exclusion Criteria:~* Therapy with gemtuzumab ozogamicin (Mylotarg) within 6 months prior to inclusion~* Allogenic transplantation within 6 months prior to inclusion~* Prior therapy (chemotherapy, targeted agents, radiotherapy) within 3 weeks except for hydroxyurea and for leukophoresis~* Previous treatment with AVE9633~* Poor kidney, liver and bone marrow functions~* Any serious active disease or co-morbid condition, which in the opinion of the principle investigator, will interfere with the safety or with compliance with the study~* Pregnant or breast-feeding women~* Patient with reproductive potential without effective birth control methods~The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: MDSC Clinical Assay in Finding and Monitoring Cancer Cells in Blood and Urine Samples From Patients With or Without Localized or Metastatic Bladder Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_CONTROL
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects must meet the criteria for one of the three following groups:~  * Normal patients- aged 40 years and older with no evidence of hematuria or cancer~ * Patients with localized bladder cancer diagnosed by cystoscopy and pathology: T2N0M0 or T3N0M0 who have not received neoadjuvant chemotherapy~ * Patients with metastatic bladder cancer: newly diagnosed with no previous treatment for metastatic disease~* Ability to understand and the willingness to sign a written informed consent~Exclusion Criteria:~* For normal subject arm: evidence of cancer or hematuria~* For localized bladder cancer: evidence of metastatic disease, second cancer, prior chemotherapy or radiotherapy within 4 weeks prior to entering the study or those who have not recovered from adverse events due to agents administered more than 4 weeks earlier~* For metastatic bladder cancer: prior therapy for metastatic disease~* Uncontrolled intercurrent illness including, but not limited to previous or current history of second malignancy unrelated to bladder cancer; autoimmune disease or immune deficiency, chronic treatment with immunomodulatory therapies (e.g. glucocorticoids); significant trauma, surgery, or infection in the past two weeks or psychiatric illness/social situations that would limit compliance with study requirements

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group I (Type: None): Patients without cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and 4 months.
- Group II (Type: None): Patients with localized bladder cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and within 4 weeks after cystectomy.
- Group III (Type: None): Patients with metastatic cancer undergo collection of blood and urine samples for analysis via MDSC clinical assay at baseline, 1 week, and within 4 weeks after completion of 4 courses of systemic chemotherapy.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Routine Post-Operative Supplemental Nutrition

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients undergoing an elective esophagectomy~* Jejunal feeding tube placed at the time of surgery~Exclusion Criteria:~* Emergent esophagectomy procedure~* Inability to provide informed consent or to complete testing or data collection~* Unwillingness to be randomized~* Tube feeding dependent on discharge

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Tube Feeding (Type: EXPERIMENTAL): Study subjects will continue to receive tube feedings (for at least 50% of caloric need) for 1-month post-operatively.
- Standard of Care (Type: NO_INTERVENTION): Tube feeding to continue in the hospital until the patient is taking adequate nutrition by mouth at post-op day #8, or upon discharge,

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Neoadjuvant Chemo for Non-metastatic Non-small Cell Lung Cancer

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients ≥ 18 years of age with either a mass suspicious for or histologically confirmed AJCC stage IB-IIIA NSCLC. For those without histologic confirmation of NSCLC, a biopsy will be done and only those patients with histologically confirmed NSCLC meeting all other eligibility criteria may proceed on protocol.~2. Mass must be determined to be surgically resectable~3. Eastern Cooperative Oncology Group (ECOG) performance status score \< 1 and a life expectancy \>3 months.~4. Participants must have at least one evaluable lesion as defined by RECIST 1.1~5. Absolute neutrophil count \> 1500 mm3, platelet count ≥ 100×109 L, hemoglobin ≥ 8.5 g/dL~6. Serum creatinine ≤1.3 mg/dL (candidate for cisplatin chemotherapy), total bilirubin ≤ 2 mg/dL, AST/ALT ≤ 5 times the upper limit of normal range~7. No prior chemotherapy or radiotherapy for NSCLC~8. At least 5 years from diagnosis of another cancer except treated in-situ disease or surgically resected non-melanoma skin cancer with clear margins.~9. Willingness to provide permission to biopsy NSCLC for collection of frozen pretreatment sample.~10. Women of child-bearing potential (i.e., women who are pre-menopausal or not surgically sterile) must be willing to use an acceptable contraceptive method (abstinence, oral contraceptive or double barrier method) for the duration of the study and for 30 days following the last dose of study drug, and must have a negative urine or serum pregnancy test within 2 weeks prior to beginning treatment on this trial~Exclusion Criteria:~1. Active clinically serious infection \> CTCAE (version 4.03) Grade 2.~2. Serious non-healing wound, ulcer, or bone fracture.~3. Major contraindication to surgical resection of NSCLC~4. Inability to complete informed consent process and adhere to the protocol treatment plan and follow-up requirements.~5. Concurrent severe illness such as active infection, or psychiatric illness/social situations that would limit safety and compliance with study requirements.~6. Patients receiving any other investigational agents.~7. Pregnant or lactating females

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cisplatin and pemetrexed (Type: EXPERIMENTAL): Cisplatin on day 1 and pemetrexed on day 1, 1 cycle = 21 days, deliver 4 neoadjuvant cycles
- Cisplatin and gemcitabine (Type: EXPERIMENTAL): Cisplatin on day 1 and gemcitabine on days 1 and 8, 1 cycle = 21 days, deliver 4 neoadjuvant cycles

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study Evaluating the Safety of the Nasal Pump

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Be at least 18 years of age~* Have provided verbal and written informed consent~* Willing to comply with all study related visits and procedures~Exclusion Criteria:~* Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 30 days prior to Visit 1.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Nasal Pump (Type: EXPERIMENTAL): Tyrvaya nasal pump with additional silicone lubricant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative Tramadol/Gabapentin/Ibuprofen Versus Tramadol/Placebo/Ibuprofen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Child must be scheduled to undergo tonsillectomy (with or without adenoidectomy)~* Child must be between the ages of 4 and 15 at the time of enrollment.~* Child and caregiver must be English-speaking~* The same caregiver (e.g., mother) must agree to complete all study assessments with child to ensure consistency~Exclusion Criteria:~* Child cannot self-assess pain due to conditions such as developmental delays, chromosomal abnormalities, or other syndromes~* Child had significant adverse effects to tramadol, gabapentin and/or ibuprofen in the past~* Child has a known underlying seizure disorder (not febrile seizure)~* Child has known underlying renal or liver dysfunction (with creatinine, aspartate aminotransferase /alanine aminotransferase, more than twice above normal value for age, respectively)~* Child is taking an selective serotonin reuptake inhibitor (SSRI), norepinephrine reuptake inhibitor (SNRI), monoamine oxidase inhibitor (MAOI) or tricyclic

- Gender: ALL
- Minimum Age: 4 Years
- Maximum Age: 15 Years
- Healthy Volunteers: f

Study Arms:
- Tramadol/gabapentin/ibuprofen (Type: ACTIVE_COMPARATOR): (A) Scheduled tramadol 1mg/kg Q6h \[max. 50mg\] for 5 days; plus tramadol 1mg/kg Q6h PRN \[max. 50mg\] for 5 days (B) Scheduled gabapentin 3 mg/kg \[max 150 mg\] Q6h for 5 days (C) PRN ibuprofen 10 mg/kg \[max. 500 mg\] Q6h PRN
- Tramadol/placebo/ibuprofen (Type: PLACEBO_COMPARATOR): (A) Scheduled tramadol 1mg/kg Q6h \[max. 50mg\] for 5 days; plus tramadol 1mg/kg Q6h PRN \[max. 50mg\] for 5 days (B) Scheduled placebo of same volume Q6h for 5 days (C) PRN ibuprofen 10 mg/kg \[max. 500 mg\] Q6h PRN

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: IFN-gamma-releasing Assay Based Approach in Patients With Suspected Tuberculous Peritonitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* all patients with suspected tuberculous peritonitis~* age 16 or more~* formal informed consent~Exclusion Criteria:~* not specified

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- conventional diagnostic flow arm (Type: NO_INTERVENTION): Perform the laparoscopic biopsy as a discretion of attending physician's decision
- two-step algorithm-based approach (Type: EXPERIMENTAL): Perform the laparoscopic biopsy as a discretion of attending physician's decision, but if the below conditions are met, do not perform the laparoscopic biopsy.~1. Blood ELISPOT \>= 6 spots or ascites adenosine deaminase \> 20 IU/L, and~2. Ascites ELISPOT/Blood ELISPOT rato \> 3

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Hypertension Monitoring in Glioma Patients Treated With Bevacizumab

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion criteria: Patients aged 18 or older with histological diagnosis of anaplastic astrocytoma (WHO grade III) or glioma (WHO grade IV) Assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons by an oncologist Patients should be on a stable or decreasing dose of steroids Willingness and ability to comply with the protocol Patient should present with a KPS of \>=70 Signed informed consent~Exclusion criteria: Previous anti-angiogenic drugs other than bevacizumab Allergy or hypersensitivity against bevacizumab Contraindications to bevacizumab according to the Summary of Product of Characteristics Unwillingness to comply with regular assessments of response and performance of study-related procedures Any condition considered relevant for proper performance of the study or risk to the patients, at the discretion of the investigator

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Glioma Patient receiving Bevacizumab (Type: None): Patients with histological diagnosis of anaplastic astrocytoma (WHO Grad III) or Glioma (WHO Grad IV)assigned to bevacizumab treatment (monotherapy or adjunctive to chemotherapy) for therapeutic reasons

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Phase III Study Comparing 3D Conformal Radiotherapy and Conformal Radiotherapy IMRT to Treat Endometrial Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* endometrial adenocarcinoma histologically proven~* post op pelvic radiotherapy~* age ≥ 70~* performance status ≤ 2~* MMSE ≥ 10~* life expectancy ≥ 3 months~* social security covered~* signed informed consent~Exclusion Criteria:~* type I stade IAGI and stade IAGIII without myometer infiltration, stade IIIc2 and IV adenocarcinoma~* uterine sarcoma~* surgery not in accordance with recommendations of Inca~* previous uncontrolled or less than 5 years prior to diagnosis cancer~* cons-indication for radiotherapy~* diarrhea ≥ 3 per day~* pelvic lymph nodes \> 1cm not resected during staging~* previous sigmoid diverticulitis, crohn disease, systemic disease, ulcerative haemorrhagic, collagenosis, infectious peritonitis~* IMRT other than tomotherapy~* photon energy \< 10MV~* patient under guardianship

- Gender: FEMALE
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 3D conformational radiotherapy (Type: ACTIVE_COMPARATOR): 25 \* 1.8 Gy in 5 weeks (=45 Gy). 3D conformational radiation
- Intensity-Modulated Radiation Therapy (Type: EXPERIMENTAL): 25 \* 1.8 Gy in 5 weeks (=45 Gy). IMRT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dose Finding Study for Combination of Capecitabine, Lapatinib and Vinorelbine in Metastatic Breast Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Written informed consent~* Able to comply with the protocol~* ECOG performance status 0-1~* Adequate contraception~* Confirmed Her2/neu-positive, adenocarcinoma of the breast~* At least one measurable lesion according to RECIST 1.1 criteria~* First or second chemotherapy after diagnosis of metastasis~* Lapatinib treatment indicated (adjuvant trastuzumab treatment \<12 months ago or progressive disease with trastuzumab treatment)~* No signs and symptoms of CHF (chronic heart failure), LVEF (left ventricular ejection fraction) at study start at least 55%~* Adequate hepatic and renal function value~* Adequate hematologic function values~Exclusion Criteria:~* Pregnant or lactating women~* Concurrent participation in another clinical trial. Prior participation is allowed if the last study medication was administered more than 4 weeks prior to randomization~* Asymptomatic with regards to tumor illness~* Previous treatment with lapatinib, capecitabine or vinorelbine~* Necessity of planned treatment with other chemotherapeutics oder anti-hormone therapy~* Major surgical procedure, open biopsy or significant traumatic injury within 28 days prior to randomization, or anticipation of the need for major surgery during the course of the study~* Evidence of cardiovascular disease, e.g. myocardial infection, unstable angina pectoris or arrhythmia~* History of vascular or cardiovascular disease within the past 6 months~* All illnesses that result in malabsorption of oral medication or inability to take oral medication~* Concurrent treatment with anti-viral drugs based on sorivudine or with aminoglycosides~* Concurrent treatment with any drug interfering with study medication, especially, those that induce CYP3A~* Concurrent treatment with allopurinol~* Other malignancies (except for basal cell carcinoma of the skin and cervical carcinoma in situ); patient can be included in the study if no recurrent disease has been observed for at least 5 years~* Concurrent illnesses or other circumstances that could interfere with trial participation, efficacy or safety of the patient

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Capecitabine, Lapatinib, Vinorelbine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy